Report Highlights

Medical Telemetry in the United States: Market Overview

The U.S. medical telemetry market was valued at USD 1.84 billion in 2024 and remains the largest national telemetry market globally. Demand is anchored in roughly 6,100 hospitals, where central station systems and bedside transmitters monitor cardiac and step-down patients. Unlike emerging markets that buy low-cost standalone monitors, U.S. buyers prioritize integrated platforms linked to Epic and Oracle Health electronic health records. Purchasing decisions turn on alarm management performance, interoperability, and total cost of ownership rather than unit price alone.

The market splits into two distinct tracks. Inpatient telemetry is mature and replacement-led, with Philips and GE HealthCare holding most central station installations under multiyear service contracts. Ambulatory cardiac monitoring is the faster-growing track, where iRhythm Technologies and Boston Scientific's Preventice unit sell reimbursed patch monitors that patients wear at home for up to two weeks. This shift is moving the point of telemetry data capture from the hospital ward into the patient's home.

Growth Drivers Behind U.S. Telemetry Demand

Three demand drivers stand out. First, Medicare reimburses extended ambulatory ECG monitoring under CPT codes 93241 through 93248, allowing cardiology practices to bill for continuous monitoring well beyond traditional 48-hour Holter studies. Second, the population is aging, with more than 58 million Americans aged 65 and older according to the U.S. Census Bureau, which steadily raises atrial fibrillation prevalence and the number of admissions requiring telemetry.

Third, the Joint Commission's National Patient Safety Goal NPSG.06.01.01 on clinical alarm safety has pushed hospitals to upgrade alarm-management software. Separately, the CMS Hospital Readmissions Reduction Program penalizes excess heart failure readmissions, prompting health systems to deploy remote telemetry after discharge. Hospitals are investing in both bedside and remote monitoring capacity as a result.

Entry Barriers in U.S. Medical Telemetry

Entry is constrained first by regulation. FDA clearance through the 510(k) pathway applies to each monitor and transmitter, and the FDA's final guidance on cybersecurity in medical devices requires a software bill of materials and a post-market vulnerability plan. New entrants should budget at least nine months for clearance and security documentation before the first hospital installation.

Incumbent and distribution barriers compound this. Philips and GE HealthCare bundle central station software with enterprise EHR integration, locking health systems into multiyear service agreements. Group purchasing organizations such as Vizient and Premier negotiate pricing that compresses margins for smaller vendors, and interference on crowded WMTS spectrum raises deployment costs for wireless transmitters.

Near-Term Telemetry Entry Opportunities in the United States

The clearest near-term opportunity is remote patient monitoring in Medicare Advantage and home health. CMS created billing codes 99453 and 99454 for remote monitoring device setup and monitoring, and Medicare billing for these services has grown sharply since 2019. Analysts estimate an addressable pool of USD 620 million in wireless cardiac monitoring for home use over the forecast period.

A second opportunity lies in ambulatory surgical centers and rural hospitals, which have historically lacked telemetry capacity. Analysts estimate USD 310 million in untapped demand across more than 1,300 critical access hospitals, which receive cost-based Medicare reimbursement that supports capital purchases of compact, cloud-connected monitors.

Market at a Glance

Leading Market Participants

• Philips
• GE HealthCare
• Medtronic
• iRhythm Technologies
• Masimo
• Baxter International
• Mindray
• Nihon Kohden
• Boston Scientific
• OSI Systems

Regulatory and Policy Environment for U.S. Telemetry

Telemetry products generally fall under FDA Class II regulation, with arrhythmia detection devices classified under product code DSK and requiring 510(k) clearance. Manufacturers must comply with the Quality Management System Regulation at 21 CFR Part 820, which the FDA is aligning with ISO 13485 under its amended rule effective February 2026. HIPAA's Security Rule governs patient data transmitted by wireless monitors and requires encryption and audit controls.

FCC Part 95 Subpart H governs Medical Telemetry Service and WMTS operation, while the Medicare Conditions of Participation at 42 CFR 482.23 set nursing and monitoring standards for hospital telemetry units. Compliance timelines are long, with FDA 510(k) reviews averaging roughly 150 days and hospital capital approvals often requiring six to twelve months. Medicare cost-based reimbursement for critical access hospitals functions as the most material public funding mechanism for telemetry purchases.

Long-Term Outlook for U.S. Medical Telemetry to 2032

By 2032 the U.S. medical telemetry market is forecast to reach USD 2.95 billion, growing at a 6.2% CAGR from 2026 to 2032. Inpatient central station revenue will grow more slowly as hospitals consolidate onto fewer platforms, while ambulatory and home-based monitoring accounts for a rising share of total spending. Reimbursement policy will remain the main determinant of where that spending lands.

Winners will combine FDA-cleared AI arrhythmia detection with cybersecurity attestations and deep EHR integration. iRhythm and Philips are positioned to capture the largest share of new value, while mid-tier vendors face pressure to demonstrate native interoperability with Epic and Oracle Health. Telemetry data will increasingly flow to cloud platforms, rewarding vendors that own the analytics layer rather than hardware alone.